We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
News & insights
Publications: 09 JUNE 2021
On Tuesday 25 May 2021, Allen & Overy IP associate Tine Carmeliet chaired a presentation with IP partner Keren Livneh and IP associate Megan McMellon and M&A associate Zara Sproul on “Drug…Read more
Publications: 15 DECEMBER 2020
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.Read more
Blog Post: 09 JUNE 2020
Further to publishing evaluation criteria for serological tests for antibodies against SARS-CoV-2 (available here), the French High Health Authority (HAS) published on 18 May 2020 its opinion on the…Read more
Blog Post: 03 JUNE 2020
Today, the French Medicines Agency (ANSM) and the Health Ministry published an update on the continuance of the work of the Scientific Committee (CST) with respect to the French medical cannabis pilot…Read more